Please find enclosed herewith the transcript of the earnings call held on May 12, 2026.
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Advanced Enzyme Technologies reported its highest-ever quarterly and annual revenue for FY26 ended March 2026. Q4 revenue was INR 2,034 million (22% YoY growth) and full-year revenue stood at INR 7,458 million (17% growth). EBITDA margin remained strong at 31% for both periods. PAT grew 69% YoY in Q4 to INR 453 million and 30% for the full year to INR 1,736 million, with margins expanding from 21% to 23%. Human Healthcare (63% of revenue) delivered 24% YoY growth in Q4. Management flagged near-term margin pressure from rising input costs (fuel, salt, solvents, packaging, logistics) due to geopolitical disruptions but expects margins to remain steady with 1-2% variability. The new R&D center in Nashik is expected to become operational in H2 FY27 with threefold capacity increase. EU approval for anti-inflammatory enzyme product is anticipated during the year, which could provide market exclusivity for 5-10 years.
Strong operational performance with margin expansion demonstrates execution capability. However, management guidance suggests limited upside from current margin levels due to input cost inflation, and the US market remains challenging with regulatory complexity. Capital allocation priorities remain under board review.